Your institution may have access to this item. Find your institution then sign in to continue.
Title
Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
Authors
Hershman, Dawn L; Buono, Donna L; Malin, Jennifer; McBride, Russell; Tsai, Wei Yann; Neugut, Alfred I
Abstract
Erythropoiesis-stimulating agents (erythropoietin and darbepoietin) have been approved to reduce the number of blood transfusions required during chemotherapy; however, concerns about the risks of venous thromboembolism and mortality exist.
Publication
Journal of the National Cancer Institute, 2009, Vol 101, Issue 23, p1633